The U.S. Food and Drug Administration (FDA) recently issued a new safety alert regarding the increased risk of Fournier’s gangrene among diabetes patients using Invokana and other drugs in the same class. Fournier’s gangrene is considered to be a rare, but very serious complication of SGLT2 inhibitors. This condition is... Read more »

A Mississippi man has filed a federal lawsuit against Janssen Pharmaceuticals that alleges that the defendant’s negligence caused him to suffer from severe, permanent medical complications. Jim Dedeaux was prescribed Invokana by his physician, a diabetes medication manufactured by the defendant. He took it as prescribed, assuming from the information... Read more »

Severe side effects of Invokana – part of a new class of diabetes drugs manufactured by J&J – have prompted a wave of litigation filed throughout the United States. Most of the Invokana lawsuits have been centralized in New Jersey federal court under MDL # 2750 for more efficient pretrial... Read more »

The makers of Farxiga, Bristol-Myers Squibb and AstraZeneca, are facing at least 18 product liability lawsuits filed in federal courts. These have now been centralized into a multidistrict litigation (MDL) pursuant to an order issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued on April 6, 2017. The... Read more »

In mid-January, the first steps in the Invokana multidistrict litigation (MDL) began. U.S. District Judge Brian Martinotti, who is presiding over the MDL in the District of New Jersey, announced 1) the pending appointment of a special mediator to deal with discovery issues and settlement possibilities and 2) a “science... Read more »

A plaintiff claims that use of diabetes drug Invokana led to kidney failure. The plaintiff only took the medication for two months before she began having life-threatening side effects that forced her to stop taking Invokana and seek medical treatment for her kidney problems. Judith Buchanan filed her lawsuit on September 16 in... Read more »

A woman that developed ketoacidosis after taking the diabetes drug Invokana has filed a lawsuit against the drug’s manufacturers. Sheryl Desalis is claiming in her complaint that Janssen Pharmaceuticals, Johnson & Johnson and Mitsubishi Tanabe Pharma failed to provide proper warnings about the risks of diabetic ketoacidosis associated with their... Read more »

The U.S. Food and Drug Administration has issued a new safety alert regarding the type 2 diabetes drug canagliflozin — Invokana and Invokamet. The Agency issued a safety announcement on May 18, notifying patients and the medical community that results of an ongoing clinical trial revealed a higher number of... Read more »

Metabolic acidosis is a risk associated with Invokana that was recently highlighted in a report by the Institute for Safe Medical Practices (ISMP). Invokana is one of the drugs recently touted for its ability to manage type 2 diabetes, but potential side effects have raised concerns and led to a... Read more »

The drug Invokana belongs to a class of Type II diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, and is referred to generically as canagliflozin. This class of drugs, which also includes well-known brands like Farxiga, Xigdua XR, Jardiance and Glyxambi, was once highly-touted as an innovative alternative for Type II... Read more »